Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) earlier this week shared insights into its strategy for 2025 during an interview with CEO Brent Willis.
The company highlighted a significant achievement in signing a letter of intent with a major multinational pharmaceutical company.
While details of the agreement remain confidential, Willis stated that this partnership reinforces Voyageur’s vertically integrated business model and enhances its credibility with institutional investors.
The company said it is well-positioned to secure the capital required for its projects, aiming to become a key producer of contrast media. Voyageur plans to market five Health Canada-licensed barium contrast products while progressing with FDA registrations.
Willis noted that the diagnostics market is growing, with GE Healthcare projecting the market size to double by 2032.
The company highlighted its approach to sourcing its own minerals, addressing supply shortages and reducing costs.
“Our vertically integrated approach allows us to provide a secure supply chain for North America while reducing costs,” said Willis.
The company also emphasized its commitment to innovation, having spent 18 months reformulating barium contrast products to enhance performance. These products are intended for FDA registration as new drugs, a move the company expects to add significant value.
Voyageur said 2025 would be pivotal as it advances milestones and establishes itself in the diagnostics sector.